Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

AHA 2018 ▼Diabetes & CVD ▼Epigenetics in CVD ▼ESC 2018 ▼Expert Meeting GLP-1, CVD & T2DM ▼HFpEF: The essentials to know ▼Invest in your arteries ▼PCSK9 ▼

HoFH

Feb. 8, 2014

Share this page with your colleagues and friends:

Continue reading:

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Lower outcome rates but more symptoms, lower QoL and undertreatment in women vs. men with HFrEF

Literature - Jan. 22, 2019 - Dewan P et al. - JACC 2019

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

Atherosclerosis

Increased risk of subclinical multi-territory non-coronary atherosclerosis with short and fragmented sleep in middle-aged subjects

Literature - Jan. 22, 2019 - Domínguez F et al. - JACC 2019

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

Consensus statement: How to identify anti-inflammatory effects of lipid-lowering therapy?

News - Jan. 8, 2019

Atrial fibrillation

Greater net clinical benefit of NOAC vs. warfarin in Asians with AF compared with non-Asians

Literature - Jan. 15, 2019 - Chao TF et al. - Eur Heart J 2018

NOAC safe and effective in NVAF patients taking at least 5 other chronic medications

Literature - Jan. 7, 2019 - Martinez BK et al., - Pharmacotherapy. 2018

DOAC treatment safe and effective in AF despite multi-morbidity

Literature - Dec. 4, 2018 - Alexander KP et al. - American Heart Journal 2018

CV Inflammation

Modest Lp(a) lowering with PCSK9 inhibitor not enough to reduce arterial wall inflammation

Literature - Jan. 9, 2019 - Stiekema LCA et al. - Eur Heart J. 2018

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Epicardial fat in HFmrEF and HFpEF patients

News - Dec. 3, 2018

CVRM

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Exploring the role of GLP-1 RA in the management of CVD & T2DM

Online-CME - Online-CME - This course consists of 5 panel discussions

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

Diabetes

Decision tool can predict individual CVD-free life-years gained and effect of treatment in T2DM

Literature - Jan. 21, 2019 - Berkelmans GFN et al. - Eur Heart J 2019

Physical activity should be stressed more in T2DM, as it reduces mortality

News - Jan. 15, 2019

Relative risk of CV events similarly increased with resting heart rate irrespective of diabetes status

Literature - Jan. 14, 2019 - Böhm M et al., - Eur Heart J 2018

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

Familial Hypercholesterolemia

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Better characterization of ASCVD risk in children with FH by measuring Lp(a) levels

Literature - Jan. 7, 2019 - Zawacki et al. - J Clin Lipidol 2018

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

News - Nov. 11, 2018

GLP-1 RA & CVD

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

Treatment benefit of GLP-1RA in elderly with T2DM may vary with age

Literature - Dec. 18, 2018 - Gilbert MP et al., - Ann Intern Med. 2018

Exploring the role of GLP-1 RA in the management of CVD & T2DM

Online-CME - Online-CME - This course consists of 5 panel discussions

Heart Failure

Lower outcome rates but more symptoms, lower QoL and undertreatment in women vs. men with HFrEF

Literature - Jan. 22, 2019 - Dewan P et al. - JACC 2019

Dyskalemia in real-world HF patients with different EF

Literature - Jan. 16, 2019 - Savarese G et al. - JACC HF 2019

Similar effects of exercise training on exercise test duration and clinical outcomes in HFrEF regardless of baseline physical activity

Literature - Jan. 15, 2019 - Mediano MFF et al. - JACC: Heart Failure. 2018

HFpEF: The essentials to know

Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

Hypertension

Lower outcome rates but more symptoms, lower QoL and undertreatment in women vs. men with HFrEF

Literature - Jan. 22, 2019 - Dewan P et al. - JACC 2019

Exercise equally effective to antihypertensive medication to lower SBP in hypertensives

Literature - Jan. 14, 2019 - Naci H et al., - Br J Sports Med 2018

SGLT2 inhibitor may give clinically relevant BP reductions in T2DM with nocturnal hypertension

Literature - Jan. 8, 2019 - Kario K et al., - Circulation. 2018

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Lipids

LDL-c as target in cardiology: The road towards lower targets

5' education - Dec. 14, 2018 - John Kastelein, Chris Packard

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Lp(a)

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

Modest Lp(a) lowering with PCSK9 inhibitor not enough to reduce arterial wall inflammation

Literature - Jan. 9, 2019 - Stiekema LCA et al. - Eur Heart J. 2018

Better characterization of ASCVD risk in children with FH by measuring Lp(a) levels

Literature - Jan. 7, 2019 - Zawacki et al. - J Clin Lipidol 2018

PAH - Q&A

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè

PCSK9

LDL-c as target in cardiology: The road towards lower targets

5' education - Dec. 14, 2018 - John Kastelein, Chris Packard

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

PCSK9 expert opinions

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

Greater net clinical benefit of NOAC vs. warfarin in Asians with AF compared with non-Asians

Literature - Jan. 15, 2019 - Chao TF et al. - Eur Heart J 2018

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

Summary | SGLT2 inhibition in cardiology: What is the profile of benefit?

Munich, Berlin - August 27, 2018

© 2006 - 2019 pace-cme.org - About